Absence of methylation-dependent transcriptional silencing in TP73 irrespective of the methylation status of the CDKN2A CpG island in plasma cell neoplasia

Απλή σελίδα τεκμηρίου
dc.contributor.authorHatzimichael, E.en
dc.contributor.authorBenetatos, L.en
dc.contributor.authorDasoula, A.en
dc.contributor.authorDranitsaris, G.en
dc.contributor.authorTsiara, S.en
dc.contributor.authorGeorgiou, I.en
dc.contributor.authorSyrrou, M.en
dc.contributor.authorStebbing, J.en
dc.contributor.authorColey, H. M.en
dc.contributor.authorCrook, T.en
dc.contributor.authorBourantas, K. L.en
dc.date.accessioned2015-11-24T19:38:35Z
dc.date.available2015-11-24T19:38:35Z
dc.identifier.issn1873-5835-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/24163
dc.rightsDefault Licence-
dc.subjectAgeden
dc.subjectAged, 80 and overen
dc.subjectBase Sequenceen
dc.subject*CpG Islandsen
dc.subject*DNA Methylationen
dc.subjectDNA Primersen
dc.subjectDNA-Binding Proteins/*geneticsen
dc.subjectFemaleen
dc.subject*Gene Silencingen
dc.subject*Genes, p16en
dc.subjectHumansen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectMultiple Myeloma/*geneticsen
dc.subjectNuclear Proteins/*geneticsen
dc.subjectPromoter Regions, Geneticen
dc.subject*Transcription, Geneticen
dc.subjectTumor Suppressor Proteins/*geneticsen
dc.subjectWaldenstrom Macroglobulinemia/*geneticsen
dc.titleAbsence of methylation-dependent transcriptional silencing in TP73 irrespective of the methylation status of the CDKN2A CpG island in plasma cell neoplasiaen
heal.abstractFew studies exist regarding the methylation status of the TP73 CpG island in plasma cell dyscrasias. We have tested whether CpG methylation of both CDKN2A and TP73 occurs in 45 individuals with multiple myeloma (24 male and 21 female, mean age 66.4 years) and in 4 patients (2 male and 2 female, mean age 61.7 years) with Waldenstrom's macroglobulinemia. No patient was found to be methylated for the promoter of TP73 while CDKN2A promoter was found to be methylated in 12/45 MM patients (26.6%) at diagnosis and in 1/4 WM patients. To verify the absence of detectable methylation observed using MSP, we performed bisulphite sequence analysis on a subset of the cases and confirmed the absence of methylation. Interesting trends were identified where patients with methylated CDKN2A had an increased risk of death (HR = 1.9, p = 0.32), advanced stage disease (DS > or = II) (OR = 1.9, p = 0.3) and anemia (OR = 1.4, p = 0.6). TP73 CpG methylation is an infrequent event in patients with MM and WM. Further evaluation in a larger sample of patients is needed in order to enhance our statistical power and to test our hypothesis that CDKN2A methylation status can become a useful prognostic biomarker.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.primary10.1016/j.leukres.2009.04.009-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/19423161-
heal.identifier.secondaryhttp://ac.els-cdn.com/S0145212609001775/1-s2.0-S0145212609001775-main.pdf?_tid=227fb9d00076afe126f9d11c12aeb53c&acdnat=1337251193_426fbdb7a4f0daafc2788de18e915940-
heal.journalNameLeuk Resen
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate2009-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ